Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
All three sickle cell disease participants treated with briquilimab successfully engrafted with neutrophil engraftment within 12-16 daysFirst two participants with...